Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Thioridazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 1.00 |
| ▸ | DRD3 known ✓ | P35462 | 4/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 1.00 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 1.00 |
| ▸ | PIM1 | P11309 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 4/20 | 1.00 |
| ▸ | DRD1 | P21728 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | HTR7 | P34969 | 3/20 | 1.00 |
| ▸ | HTR6 | P50406 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thioridazine SCHEMBL9566 | 1.00 | PIM1 (1.00) | PIM1CYP2D6DRD2CYP1A2HTR1A | |
| Thioridazine SCHEMBL380206 | 1.00 | PIM1 (1.00) | PIM1CYP2D6DRD2CYP1A2HTR1A | |
| Thioridazine SCHEMBL12434241 | 1.00 | PIM1 (1.00) | PIM1CYP2D6DRD2CYP1A2HTR1A | |
| Thioridazine SCHEMBL2577719 | 1.00 | PIM1 (1.00) | PIM1CYP2D6DRD2CYP1A2HTR1A | |
| Thioridazine SCHEMBL29387384 | 0.99 | TDP1 (1.00) | PIM1CYP2D6DRD2CYP1A2HTR1A | |
| Thioridazine SCHEMBL41430 | 0.99 | TDP1 (1.00) | PIM1CYP2D6DRD2CYP1A2HTR1A | |
| Thioridazine SCHEMBL8006297 | 0.99 | TDP1 (1.00) | PIM1CYP2D6DRD2CYP1A2HTR1A | |
| Thioridazine SCHEMBL30827481 | 0.99 | TDP1 (1.00) | PIM1CYP2D6DRD2CYP1A2HTR1A | |
| Thioridazine SCHEMBL56533 | 0.98 | PIM1 (0.96) | PIM1CYP2D6DRD2CYP1A2HTR1A | |
| Thioridazine SCHEMBL28133267 | 0.94 | CYP2D6 (0.89) | PIM1CYP2D6DRD2CYP1A2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4121058-B1 | OXAZOLIDINONE COMPOUND AND ITS USE THEREOF AS AN ANTIBACTERIAL AGENT | MERCK SHARP & DOHME LLC (US) | 2026-02-18 | — | — | EP | claimed |
| EP-3731848-B1 | TARGETING THE CBM SIGNALOSOME COMPLEX INDUCES REGULATORY T CELLS TO INFLAME THE TUMOR MICROENVIRONMENT | MASSACHUSETTS GEN HOSPITAL (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12600766-B2 | Anti-TDP-43 binding molecules and uses thereof | AC IMMUNE SA (CH) | 2026-04-14 | — | — | US | disclosed |
| US-20260022411-A1 | MICROBIAL CELL FACTORIES PRODUCING THIAMINE | BIOSYNTIA APS (DK) | 2026-01-22 | — | — | US | disclosed |
| US-20250361572-A1 | MULTIPLEXED PATHOGEN DETECTION USING NANOPLASMONIC SENSOR FOR HUMAN PAPILLOMAVIRUS | NANOPATH INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-12454520-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| EP-4631467-A2 | FRONT-LOADABLE FLUID TRANSFER ASSEMBLIES AND RELATED MEDICAL FLUID TRANSFER SYSTEMS AND METHODS | ClearPoint Neuro, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE LTD (SG) | 2025-09-04 | — | — | US | disclosed |
| US-20250262268-A1 | Methods and Compositions for Inhibiting Viral Infection | NEW YORK UNIVERSITY | 2025-08-21 | — | — | US | disclosed |
| US-20250264459-A1 | IN VITRO ASSAY TO PREDICT CARDIOTOXICITY | STEMINA BIOMARKER DISCOVERY INC (US) | 2025-08-21 | — | — | US | disclosed |
| EP-4025304-A1 | THIORIDAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | Universita' Degli Studi Di Padova (IT) | 2022-07-13 | — | — | EP | disclosed |
| EP-4025304-A1 | THIORIDAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | Universita' Degli Studi Di Padova (IT) | 2022-07-13 | — | — | EP | disclosed |
| CN-114716489-A | Targeting ligand and application thereof in therapeutic nucleic acid conjugate | 纳肽得有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-11369566-B2 | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | ALK-ABELLÓ, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| CN-114642742-A | Multiple stimulus response nano material-high molecular composite hydrogel and preparation method thereof | 南京邮电大学 | 2022-06-21 | — | — | CN | disclosed |
| WO-2022101676-A1 | MATERIALS AND METHODS OF TREATING CANCER | MONOPTEROS THERAPEUTICS,INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| EP-3996697-A1 | NOVEL PFAR-INHIBITING COMPOUNDS | Université de Bretagne Occidentale (U.B.O.) (FR) | 2022-05-18 | — | — | EP | disclosed |
| EP-3993864-A1 | EXTENSION TUBE ASSEMBLY AND RELATED MEDICAL FLUID TRANSFER SYSTEMS AND METHODS | ClearPoint Neuro, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| EP-3972692-A1 | ANTI-TDP-43 BINDING MOLECULES AND USES THEREOF | AC Immune SA (CH) | 2022-03-30 | — | — | EP | disclosed |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600766-B2 | Anti-TDP-43 binding molecules and uses thereof | TARDBP, CDR2, FUS | DRD2 557/4885DRD3 435/4885HTR2A 2355/4885 |
| US-12454520-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | DRD2 4552/4885DRD3 4576/4885HTR2A 3472/4885 |
| US-11369566-B2 | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | OTC, OAT, MYOC | DRD2 4404/4885DRD3 4294/4885HTR2A 2362/4885 |
| US-20260022411-A1 | MICROBIAL CELL FACTORIES PRODUCING THIAMINE | AHCY, SHMT1, MTHFD1 | DRD2 3373/4885DRD3 3347/4885HTR2A 1691/4885 |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | DRD2 4742/4885DRD3 4814/4885HTR2A 934/4885 |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | UPF1, NLN, BRCA1 | DRD2 4318/4885DRD3 4400/4885HTR2A 3360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.